Pictures are always worth a thousand words. Our physicians provide experienced, trustworthy care that is carefully tailored to our patient’s needs. We invite you to schedule a consult to explore the best preventative and restorative options for your skin.
BOTOX®
Photos taken at full smile before and after treatment with BOTOXR® Cosmetic (onabotulinumtoxinA) at day 7. In two clinical studies, 26.1% and 20.3% of people had ≥ 2-grade improvement at day 30. In one of these studies, 67.9% of people had mild or no crow’s feet at day 30 after treatment.
Before |
After (Day 7) |
Before |
After (Day 7) |
Before |
After (Day 7) |
Before |
After (Day 7) |
Before |
After (Day 7) |
Before |
After (Day 7) |
Before |
After (Day 7) |
Before |
After (Day 7) |
Botox WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and upper limb spasticity and at lower doses.
DERMAL FILLERS
JUVADERM XC® & JUVADERM XC ULTRA PLUS®
Before |
After (2 Weeks) |
Before |
After (2 Weeks) |
| Model was treated for parentheses lines (JUVEDERM® Ultra, 0.5 mL; JUVEDERM® Ultra Plus, 1.5 mL), marionette lines (JUVEDERM® Ultra, 0.3 mL; JUVEDERM® Ultra Plus, 0.5 mL), and corner lines (JUVEDERM® ltra, 0.2 mL; JUVEDERM® Ultra Plus, 0.2 mL). | Model was treated for marionette lines (JUVEDERM® Ultra, 1.05 mL; JUVEDERM® Ultra Plus, 1.35 mL0, parentheses lines (JUVEDERM® Ultra, 0.8 mL; JUVEDERM® Ultra Plus, 0.3 mL), corner lines (JUVEDERM® Ultra, 0.25 mL; JUVEDERM® Ultra Plus, 0.25 mL), and vertical lip lines (JUVEDERM® Ultra, 0.1 mL; JUVEDERM® Ultra Plus, 0.1 mL). |
WARNING:
Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled
VOLUMA XC®
Unretouched photos of paid model taken 1 month after treatment. A total of 4.0 mL of JUVÉDERM VOLUMA® XC was injected into the zygomatic arch, anteromedial cheek, and submalar region.
In the clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.
Unretouched photos of paid model taken 1 month after treatment. A total of 3.0 mL of JUVÉDERM VOLUMA® XC was injected into the zygomatic arch, anteromedial cheek, and submalar region.
In the clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions
Unretouched photos of paid model taken 1 month after treatment. A total of 3.5 mL of JUVÉDERM VOLUMA® XC was injected into the zygomatic arch, anteromedial cheek, and submalar region. In the clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimalcorrection for all 3 subregions.
BELLAFILL®
Actual Bellafill® patients, individual results may vary.
